{"altmetric_id":1612411,"counts":{"readers":{"mendeley":25,"citeulike":0,"connotea":0},"total":{"posts_count":2},"twitter":{"unique_users_count":2,"unique_users":["FrancescoTurtu1","Lymphoma_Doc"],"posts_count":2}},"selected_quotes":["MicroRNA signature may help determine if mantle cell or other lymphomas are aggressive, add to clinical prognostics.","MicroRNA Signature Potential Prognostic Value in Mantle-Cell Lymphoma"],"citation":{"abstract":"Mantle-cell lymphoma (MCL) has a variable natural history but is incurable with current therapies. MicroRNAs (miRs) are useful in prognostic assessment of cancer. We determined an miR signature defining aggressiveness in B-cell non-Hodgkin lymphomas (NHL) and assessed whether this signature aids in MCL prognosis.","abstract_source":"pubmed","altmetric_jid":"4f6fa5e93cf058f610005a18","authors":["R. S. Goswami","E. G. Atenafu","Y. Xuan","L. Waldron","P. P. Reis","T. Sun","A. Datti","W. Xu","J. Kuruvilla","D. J. Good","R. Lai","A. J. Church","W. S. Lam","T. Baetz","D. P. LeBrun","L. H. Sehn","P. Farinha","I. Jurisica","D. J. Bailey","R. D. Gascoyne","M. Crump","S. Kamel-Reid","Rashmi S. Goswami","Eshetu G. Atenafu","Yali Xuan","Levi Waldron","Patricia P. Reis","Thomas Sun","Alessandro Datti","Wei Xu","John Kuruvilla","David J. Good","Raymond Lai","Alanna J. Church","Wilson S. Lam","Tara Baetz","David P. LeBrun","Laurie H. Sehn","Pedro Farinha","Igor Jurisica","Denis J. Bailey","Randy D. Gascoyne","Michael Crump","Suzanne Kamel-Reid"],"doi":"10.1200\/jco.2012.45.3050","first_seen_on":"2013-07-09T12:01:15+00:00","funders":["cihr"],"issns":["0732-183X","1527-7755"],"journal":"Journal of Clinical Oncology","last_mentioned_on":1373472048,"links":["http:\/\/jco.ascopubs.org\/content\/early\/2013\/07\/03\/JCO.2012.45.3050.long"],"pmid":"23835716","pubdate":"2013-07-08T00:00:00+00:00","publisher_subjects":[{"name":"Oncology And Carcinogenesis","scheme":"era"}],"scopus_subjects":["Health Sciences","Medicine","Life Sciences","Biochemistry, Genetics and Molecular Biology"],"subjects":["neoplasms"],"title":"MicroRNA Signature Obtained From the Comparison of Aggressive With Indolent Non-Hodgkin Lymphomas: Potential Prognostic Value in Mantle-Cell Lymphoma","type":"article","mendeley_url":"http:\/\/www.mendeley.com\/research\/microrna-signature-obtained-comparison-aggressive-indolent-nonhodgkin-lymphomas-potential-prognostic"},"altmetric_score":{"score":1,"score_history":{"1y":0,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":1},"context_for_score":{"all":{"total_number_of_other_articles":8065840,"mean":6.8434648965807,"rank":4265264,"this_scored_higher_than_pct":27,"this_scored_higher_than":2237729,"rank_type":"exact","sample_size":8065840,"percentile":27},"similar_age_3m":{"total_number_of_other_articles":125082,"mean":6.9911703775954,"rank":59084,"this_scored_higher_than_pct":40,"this_scored_higher_than":50577,"rank_type":"exact","sample_size":125082,"percentile":40},"this_journal":{"total_number_of_other_articles":8561,"mean":14.06674228972,"rank":6747,"this_scored_higher_than_pct":11,"this_scored_higher_than":977,"rank_type":"exact","sample_size":8561,"percentile":11},"similar_age_this_journal_3m":{"total_number_of_other_articles":72,"mean":10.098028169014,"rank":42,"this_scored_higher_than_pct":22,"this_scored_higher_than":16,"rank_type":"exact","sample_size":72,"percentile":22}}},"demographics":{"poster_types":{"member_of_the_public":2},"users":{"twitter":{"cohorts":{"Members of the public":2}},"mendeley":{"by_status":{"Professor > Associate Professor":2,"Researcher":8,"Student  > Ph. D. Student":7,"Student  > Postgraduate":1,"Student  > Master":4,"Other":2,"Student  > Doctoral Student":1},"by_discipline":{"Medicine and Dentistry":10,"Agricultural and Biological Sciences":12,"Biochemistry, Genetics and Molecular Biology":2,"Unspecified":1}}},"geo":{"twitter":{"US":2},"mendeley":{"CA":1,"NL":1}}},"posts":{"twitter":[{"url":"http:\/\/twitter.com\/FrancescoTurtu1\/statuses\/354570596824252416","license":"public","citation_ids":[1612411],"posted_on":"2013-07-09T11:59:52+00:00","author":{"name":"Francesco Turturro","url":"http:\/\/faculty.mdanderson.org\/Francesco_Turturro\/Default.asp?SNID=1484660469","image":"https:\/\/pbs.twimg.com\/profile_images\/763530448618217472\/8el8ozjZ_normal.jpg","description":"Lymphoma specialist expressing his own opinions","id_on_source":"FrancescoTurtu1","tweeter_id":"1191609930","geo":{"lt":29.76328,"ln":-95.36327,"country":"US"},"followers":968},"tweet_id":"354570596824252416"},{"url":"http:\/\/twitter.com\/Lymphoma_Doc\/statuses\/354993617087107073","license":"public","citation_ids":[1612411],"posted_on":"2013-07-10T16:00:48+00:00","author":{"name":"Jason Westin, MD","url":"http:\/\/faculty.mdanderson.org\/Jason_Westin\/Default.asp","image":"https:\/\/pbs.twimg.com\/profile_images\/421286714980564992\/oK71J2om_normal.jpeg","description":"Lymphoma Specialist at MD Anderson Cancer Center, dreamer and doer, averse to status quo. Opinions are mine.","id_on_source":"Lymphoma_Doc","tweeter_id":"1080058020","geo":{"lt":29.76328,"ln":-95.36327,"country":"US"},"followers":3331},"tweet_id":"354993617087107073"}]}}